Avacta previews AVA6103 pharmacokinetic data as sustained-release cancer drug faces first human test
Avacta’s next AVA6103 data will test sustained exatecan release in cancer patients. Read what the FOCUS-01 results could mean for its platform.
Features & Analysis
Features & Analysis
Avacta secures single-trial FDA path for AVA6000, but can its low-FAP cancer signal survive a pivotal test?
Avacta Group PLC has agreed a potential full-approval pathway for faridoxorubicin with the United States Food and Drug Administration, while new clinical analyses suggest the drug may work even in tumours with very low FAP expression. The pivotal opportunity is becoming clearer, but Avacta still needs mature progression-free survival data, a development partner and evidence
Pharma & Biotech
Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Pharma & Biotech
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves
Pharma & Biotech
Avacta Therapeutics (LSE: AVCT) advances FAP-targeting drug conjugate AVA6103 into Phase 1: What’s at stake?
Avacta Therapeutics (LSE: AVCT) has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration for AVA6103 (also known as FAP-Exd), its second clinical-stage asset developed using the company’s proprietary pre|CISION platform. The IND clearance enables the start of a Phase 1 trial evaluating the safety, tolerability, and dose parameters of